JAMES GREER: Open Payments
NPI 1548268303 · PROVIDENCE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$175,662 in 205 payments from 9 companies in 2025. Trend: 2023 $116,251 · 2024 $178,460 · 2025 $175,662
Speaker / faculty: $131,721Consulting: $28,075Travel & lodging: $9,620Food & beverage: $6,247
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 81 | $71,669 |
| Teva Pharmaceuticals USA, Inc. | 27 | $24,642 |
| Neurocrine BioSciences, Inc. | 25 | $23,091 |
| Vanda Pharmaceuticals Inc. | 26 | $21,459 |
| Alkermes, Inc. | 22 | $18,196 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $16,451 |
| Axsome Therapeutics, Inc. | 1 | $113 |
| Indivior Inc. | 1 | $24 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
Products named: COBENFY, UZEDY, INGREZZA, FANAPT, LYBALVI, CAPLYTA, ARISTADA, Auvelity.
Industry payments across RI — which companies pay providers there.
